RESEARCH ARTICLE

Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study

Agustín Ciapponi1*, Sacha Alexis Virgilio1, Mabel Berrueta1, Natalie Claire Soto1, Álvaro Ciganda1, Moisés Freddy Rojas Illanes2, Briseida Rubio Martínez2, Johana Gamba3, Carlos Arturo González Salazar3, José Nicolás Rocha Rodríguez3, Bruno Scarpellini4, Ana María Bravo Perdomo5, Gerardo Machnicki6, Leandro Aldunate6, Juan De Paula7, Ariel Bardach1

1 Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 2 Hospital Dr. Bernardo Sepúlveda, Mexico DF, Mexico, 3 Fundación Universitaria Sánitas, Bogotá, Colombia, 4 Janssen-Cilag Farmacéutica Ltda, São Paulo, Brazil, 5 Janssen-Cilag Farmacéutica Ltda, Bogotá, Colombia, 6 Janssen-Cilag Farmacéutica Ltda, Buenos Aires, Argentina, 7 Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina

* aciapponi@iecs.org.ar

Abstract

Background and aims
Ulcerative Colitis (UC) and Crohn’s Disease (CD) have a major impact on quality of life and medical costs. The aim of the study was to estimate the prevalence, incidence and clinical phenotypes of Inflammatory Bowel Disease (IBD) cases in Mexico and Colombia.

Methods
We analyzed official administrative and health databases, used mathematical modelling to estimate the incidence and complete prevalence, and performed a case-series of IBD patients at a referral center both in Mexico and Colombia.

Results
The age-adjusted complete prevalence of UC per 100,000 inhabitants for 2015/2016 ranged from 15.65 to 71.19 in Mexico and from 27.40 to 69.97 in Colombia depending on the model considered. The prevalence of CD per 100,000 inhabitants in Mexico ranged from 15.45 to 18.08 whereas in Colombia, the age-adjusted incidence of CD ranged from 0.30 to 0.57.

In Mexico, the age-adjusted incidence of UC per 100,000 inhabitants per year ranged from 0.90 to 2.30, and from 0.55 to 2.33 in Colombia. The incidence for CD in Mexico ranged from 0.35 to 0.66 whereas in Colombia, the age-adjusted incidence of CD ranged from 0.30 to 0.57.

The case-series included 200 IBD patients from Mexico and 204 patients from Colombia. The UC/CD prevalence ratio in Mexico and Colombia was 1.50:1 and 4.5:1 respectively. In
study design, data collection and analysis or decision to publish.

Competing interests: This work was funded by Janssen-Cilag Pharmaceutical. This does not alter our adherence to PLOS ONE policies on sharing data and materials. In the synthesis of the main results of the study as well as in the development of the writing of the manuscript did not interfere any interest. In addition to this, the present study is of the epidemiological type, where the main results are related to the estimation of prevalence and incidence of the disease, so we consider that it is still difficult for them to be influenced by interests outside those of the main researchers. There are no patents, products in development or marketed products evaluated in this research to declare.

Mexico, the female/male prevalence ratio for UC was 1.50:1 and 1.28:1 for CD, while in Colombia this ratio was 0.68:1 for UC and 0.8:1 for CD. In Mexico the relapse rate for UC was 63.3% and 72.5% for CD, while those rates in Colombia were 58.2% for UC and 58.3% for CD.

Conclusions
The estimated burden of disease of IBD in Mexico and Colombia is not negligible. Although these findings need to be confirmed by population-based studies, they are useful for decision-makers, practitioners and patients with this condition.

Introduction
Inflammatory bowel disease (IBD) is a term encompassing two main inflammatory diseases of the colon and/or small intestine: Crohn’s disease (CD) and Ulcerative Colitis (UC).[1] Diagnosis is based on clinical presentation, endoscopic findings and other imaging and histopathologic findings. Both diseases are chronic and clinically intermittent with remissions and relapses, possibly due to interactions between genetic and environmental factors.[2] Differentiation between UC and CD is not always clear as symptoms overlap and extra-intestinal manifestations can be similar. Treatment of inflammatory bowel disease includes lifestyle changes (e.g., smoking cessation for patients with CD), medical management, and surgical interventions.[1]

IBDs have a major impact on life expectancy, quality of life and medical costs. For example, patients with Crohn’s disease have a risk of dying over 50% higher than someone in the general population of the same age.[3] IBD burden derives in an important increase of direct medical costs, although this may vary across countries. A Canadian study showed that IBD doubles healthy controls direct costs and that CD is on average 20% costlier than UC.[4]

Regarding UC, the cause of the disease is unknown; however, over-stimulation of an inadequately regulated mucosal immune system appears to be a major pathophysiological pathway. The course of the disease is generally relapsing–remitting, with patients experiencing few or no gastrointestinal symptoms in between symptomatic flare-ups (relapses).

The prevalence of UC in Europe and USA reaches 70–150 patients per 100,000 inhabitants.[5] The overall mortality rates for CD have decreased around the world in the last twenty years, but based on recently published nationwide data there is still excess mortality during the disease course.[6,7] Mortality rates in CD vary in different regions of the world, that may be related with different genetic, environmental, and health care related conditions.[6,7] IBD’s epidemiology is well characterized in developed countries, but this is less so in Latin America (LA). However, a study reports that since 1990 IBD incidence has been rising in newly industrialized countries in South America and other regions[8]. A systematic review including LA reported considerably lower prevalence rates for said region than for others[9] and marked differences in the burden of the disease among countries. Environmental factors such as socio-economic status, exposure to infections, use of antibiotics and issues of hygiene, might help explain the epidemiological differences between populations.[10]

Some studies have attempted descriptions of the epidemiology of IBD in Latin America. [11–18] UC incidences ranged from 0.74 to 6.76 per 100,000 inhabitants, 0.24 to 3.50 for CD, and 0.42 to 2.46 for non-specified IBD. UC prevalence ranged from 0.99 to 44.3 per 100,000 inhabitants, 0.24 to 14.90 for CD and 0.42 to 38.22 for non-specified IBD.[18] Some case-series
and descriptive studies also describe some features of these conditions in patients of LA. [19–24]

Despite the little evidence from the IBD patients in Latin America, our hypothesis is that the burden of disease in LA is not marginal. Considering this panorama of scarcity of epidemiological, clinical and resource use information, we aimed at conducting a study to estimate the prevalence, incidence and clinical phenotypes of IBD in Mexico and Colombia, two large countries of the region for which data is also lacking.

Materials and methods

We performed a retrospective observational study following the Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) guidelines.[25] During 2018, we included data from official administrative and health databases in Mexico and Colombia. We used the tenth revision of the International Classification of Diseases (ICD 10) IBD, selecting codes K50x (for CD) and K51x (for UC). We also explored related ICD codes, as K564: Other obstructions of the intestine, K63 Other diseases of the intestines, K638 Other specified diseases of the intestine, K639 Intestinal disease, unspecified, K591 Functional diarrhea, M075 Joint disease in ulcerative colitis, M095 Juvenile arthritis in ulcerative colitis and K529 Colitis and gastroenteritis not infectious, not specified. However, we decided not to include these additional codes because of their very low specificity. Because the capture-recapture approach requires the inclusion of health facilities serving at least 80% of the population from a geographic area to estimate the target disease epidemiology with reasonable reliability, and this type of centers does not exist in Mexico and Colombia, we had to resort to alternative methods.

We therefore analyzed official administrative databases, modelling incidence and prevalence with mathematical models.

Mexico data

As part of the process of estimation of prevalence and incidence of IBD cases in Mexico, which relate to the true burden of disease, we initially analyzed databases with information on hospital discharges by IBD, sex and age group generated by the Mexican public health sector.

Public sector discharge records were obtained from a standard-format database of hospital discharges in the health sector (2009–2015), which is available on the website of the National Health Information System (Sistema Nacional de Información en Salud—SINAIS) of the General Directorate of Health Information (Dirección General de Información en Salud—DGIS).[26] This database includes more than 40 million hospital discharge records during the evaluated period and provides basic information such as year of care, sex, age of patient, and main condition. The records are coded according to the ICD-10,[27] length of stay, reason for discharge, and hospital discharges from the care institution, and have been compiled by the Ministry of Health, the Mexican Social Security Institute (Instituto Mexicano del Seguro Social—IMSS), Oportunidades IMSS, the Institute for Social Security and Services for State Workers (Instituto de Seguridad Social y Servicios para Trabajadores del Estado—ISSSTE), PEMEX and the Mexican Navy (SEMAR). According to the Official Mexican Standard, hospital discharges information includes number of discharges due to cure, improvement, transfer to another hospital unit, death or discharge, and excludes transfers between different services within the hospital.[28] It is important to consider that while hospital discharge records compile data for each event, a person can be admitted to the hospital on different occasions for the same cause or for various reasons in the same period. In order to capture this phenomenon, we used also the reported number of hospitalizations from the DGIS database.[26]
For Mexico, the Population Council of Mexico (CONAPO) provided the population projections data for different calendar years.[29] The mortality data for the study period come from the General Directorate of Health Information (DGIS).[30]

**Colombia data**

We obtained the number of patients with IBD as primary diagnosis from the Integral Information System of Social Protection (SISPRO) database.[31] The SISPRO database, hosted by the Colombian Ministry of Health and Social Protection, offers consolidated data coming from all healthcare providers (hospitals and healthcare centers), which are obliged by law to report data using the ICD-10 coding for the primary diagnosis, for all registered persons who demand services within the Social Security Health System. It is considered that more than 90% of Colombians are registered with SISPRO.

SISPRO does not provide information on IBD patients not reaching the healthcare system, and thus there is no available data about them. To estimate the yearly incidence, we considered a “new case” to be a person with a positive diagnosis not previously identified, who required Health Services for the first time and is recorded as an IBD patient for the first time in SISPRO.

Official demographic information and vital statistics were obtained from the National Administrative Department of Statistics (DANE). [32]

Prevalence of persons with IBD contacting the health system out of the total registered population was used as a proxy of real prevalence. Incidence per 100,000 population-years was based on the annual frequency of new IBD cases contacting the health system. These contacts could be either emergency visits, ambulatory consultations and/or hospital discharges.

**Modelling**

We also used mathematical modelling to estimate the incidence and complete prevalence. DisMod II model is a multistate life table that simulates the epidemiological progress of a single disease by exploiting the fact that parameters such as incidence, prevalence, remission, case fatality and mortality rates are not independent variables.[33] Hence, it was designed to estimate epidemiological parameters on diseases when the availability of measured data is scarce.

We used the Mexican and Colombian prevalence of the Institute of Health Metrics’ Global Burden of Disease project, estimated with Disease Modeling Multiregression (DISMOD-MR) as our input for the DISMOD II model for the years 2010 and 2016, for which data was available.[34][35] We assumed zero remission rate.

We also ran MIAMOD, a model originally developed for cancer complete prevalence estimates.[36,37] It uses a back-calculation method that could be applied to estimate the incidence and complete prevalence of IBD, as a chronic condition, from specific age-gender mortality and survival as inputs.[37] Mortality came from DGIS, and survival was extrapolated from Danish IBD cases, being Denmark a country with extensive high-quality surveillance information. Regarding the degree of coverage of mortality data we used WHO’s Global Health Observatory.[38] Mortality input values for models were adjusted for this type of under-reporting, which was 5.5% for Mexico and 6% for Colombia, according to UN tables.[38] In order to estimate complete prevalence figures with MIAMOD we performed a sensitivity analysis considering an additional correction of 10%, due to garbage coding, anticipating that this is the model that provides the upper limit estimations.

**Cases-series**

Regarding clinical phenotypes of disease, during 2018 we chose two centers: Hospital Dr. Bernardo Sepúlveda, Colorectal surgery Department, in Mexico City, Mexico; and Clínica...
Universitaria Colombia–EPS Sánitas in Bogotá, Colombia. Those centers collected retrospectively a case-series of patients under clinical follow-up. These large referral centers included both outpatients and inpatients, and the diagnosis of IBD was established according to the most updated diagnostic recommendations for IBD. This included clinical features, endoscopy of the colon, other biochemical and imaging procedures like video capsule or pan-endoscopy, and biopsy. The date of IBD diagnosis was considered the starting point of the disease follow-up, and the symptoms onset date was recorded separately. We gathered demographic data of patients, family history of IBD, disease anatomical extension, severity of disease at the time of diagnosis, signs and symptoms, hospitalization episodes, relapse dates, and treatment patterns.

We used a sample of 200 consecutive cases from the routine database of the clinic cases that allow ±5% of semi-amplitude of the 95% confidence interval for the proportions of those least frequent symptoms. Univariate statistical analyses were performed to outline the study population. Wilcoxon test and $\chi^2$ tests were done to determine differences in continuous and categorical variables, respectively. Dependent variable, UC clinical remission, was analyzed according to the main variables collected, through a multivariable regression analysis. We presented central estimations with their 95% confidence Intervals (CI), both in tables and in graphical format. We performed these analyses using Stata statistical software (v. 14.1, StataCorp, College Station, TX).

The study was approved by the Ethics Committee of the Instituto Mexicano del Seguro Social (IMSS), Ref. 09-B5-61-2800/20180 and by the Research Ethics Committee of the Fundación Universitaria Sánitas, Bogotá Colombia, Act 017–18.

Results

Epidemiology in Mexico

Data from Mexican administrative databases allowed us to present discharge rates by IBD but did not allow us to estimate incidence or prevalence of disease. In S1 and S2 Files, we present the overall and by-age group rates per 100,000 population of hospital discharges by IBD type and sex, and the discharge rates by age groups from 2010 to 2015 to complement our epidemiological estimates based on SINAIS data.

We present the results using mathematical modelling (DISMOD II AND MIAMOD) to estimate the incidence and complete prevalence.

The age-adjusted complete prevalence of UC per 100,000 inhabitants for 2015/2016 ranged from 15.65 to 71.19, depending on the model considered. The prevalence of CD per 100,000 inhabitants, ranged from 15.45 to 18.08. The age-adjusted incidence of UC per 100,000 inhabitants per year, ranged from 0.90 to 2.30, and for CD ranged from 0.35 to 0.66 using both models. The prevalence by sex for 2010 and 2015/2016 is presented in Table 1.

The MIAMOD adjusted prevalence was twice as high as the DisMod II for men and six times the value for females, and regarding CD they were quite similar.

The MIAMOD adjusted was 1.5 and three times higher than the DisMod II in male and female UC incidence, respectively. We found similar female CD incidence and around two times higher for males (Table 1).

The female-male ratio for UC prevalence was 2.1: 1 and for the CD prevalence was 0.8:1 (MIAMOD) and 0.7:1 and 1:1 using DisMod II.

Epidemiology in Colombia

We collected information of the years 2010–2015 from SISPRO, the most complete from the database inception. We found a total of 51,330 people who consulted with the Colombian Health System between 2010 and 2015. These people visited different centers whose data are
submitted to the SISPRO registry. Table 2 shows the information from this database, presenting the yearly number of people who have been admitted to hospitals, who have used the emergency services and who have received medical procedures due to inflammatory bowel disease at the outpatient setting.

The frequency of drugs prescriptions in patients with IBD came from a sub-database of SISPRO including 837 patients who received specific IBD medication during the period 2010 to 2015. There was no data available for the calendar year 2012. About 72% (n = 599) received azathioprine while 56% (n = 469) and 36% (n = 305) received mesalazine and steroids, respectively.

According to our results, in Colombia the age-adjusted complete prevalence of UC per 100,000 inhabitants for 2015/2016 ranged from 27.40 to 69.97 depending on the model considered. The prevalence of CD per 100,000 inhabitants, ranged from 16.75 to 18.43. The age-adjusted incidence of UC per 100,000 inhabitants per year, ranged from 0.55 to 2.33, and for CD ranged from 0.30 to 0.57, respectively. These estimations were very similar to the 2010 estimations. The separate estimations by gender are presented in Table 3. The MIAMOD adjusted complete prevalence was 2 to 3 times higher than the DisMod II prevalence for UC and from 0.7 to 1.4 for CD. The MIAMOD adjusted incidence was 2 to 3 times higher than the DisMod II.

### Table 1. Mexico 2010–16. Comparison of complete population prevalence and incidence rates of total IBD, as modelled by DisMod II and MIAMOD for the years 2010 and 2015/16.

| Outcomes | Years | Ulcerative Colitis | | | | Crohn’s Disease | | |
|---|---|---|---|---|---|---|---|---|
| | Male | Female | Male | Female | Male | Female | Male | Female |
| Prevalence | 2010 | 19.20 | 39.80 | 43.90 | 17.79 | 84.08 | 98.30 | 21.16 | 18.15 | 20.02 | 16.71 | 14.63 |
| | 2015/16 | 17.00 | 39.84 | 43.95 | 14.3 | 84.20 | 98.43 | 20.50 | 18.16 | 20.05 | 14.40 | 14.65 |
| Incidence | 2010 | 1.00 | 1.41 | 1.55 | 0.68 | 2.65 | 3.05 | 0.30 | 0.68 | 0.75 | 0.30 | 0.52 |
| | 2015/16 | 1.00 | 1.41 | 1.55 | 0.80 | 2.65 | 3.05 | 0.30 | 0.68 | 0.75 | 0.40 | 0.52 |

Prevalence inputs based on DISMOD-MR [34][35]
†22 (2010) and 21 (2016)
†16 (2010) and 15 (2016)
*13 (2010) and 12 (2016)
**10 (2010) and 8.4 (2016).

*Results from MIAMOD with an adjusted of 10% in the specific mortality data; NE: Not Estimated.

https://doi.org/10.1371/journal.pone.0228256.t001

### Table 2. Colombia 2010–15. Number of hospital discharges, emergency and outpatient visits, by IBD type and sex (all ages).

| Year | Ulcerative Colitis | | | | Crohn’s Disease | | |
|---|---|---|---|---|---|---|---|
| | Males | Emerg. | Outp. | Hospital | Emerg. | Outp. | Hospital | Emerg. | Outp. | Hospital | Emerg. | Outp. |
| 2010 | 137 | 129 | 3003 | 181 | 185 | 4166 | 20 | 25 | 487 | 10 | 23 | 801 |
| 2011 | 182 | 201 | 3639 | 252 | 266 | 4858 | 30 | 43 | 527 | 25 | 39 | 736 |
| 2012 | 211 | 280 | 4013 | 248 | 364 | 5355 | 39 | 53 | 526 | 38 | 65 | 643 |
| 2013 | 189 | 326 | 4190 | 217 | 395 | 5614 | 32 | 48 | 520 | 21 | 56 | 733 |
| 2014 | 224 | 385 | 4655 | 254 | 535 | 6291 | 43 | 58 | 603 | 32 | 67 | 796 |
| 2015 | 211 | 253 | 4124 | 268 | 342 | 5689 | 45 | 34 | 501 | 37 | 49 | 643 |

Source: SISPRO database

https://doi.org/10.1371/journal.pone.0228256.t002
II incidence for UC (although seven times higher for females) and from 1.6 to 2.3 times higher for CD. Regarding the comparison with SISPRO, the MIAMOD adjusted prevalence was 3 to 4 times higher than the cumulative proportion of UC patients registered in SISPRO, and 5 to 7 times higher for patients affected of CD.

In the S2 File we show the prevalence of IBD by sex and age group estimated using the MIAMOD model base case for both countries. The S1 File show the Colombian prevalence of UC and CD among health system users by age group from 2010 to 2015.

Case-series

We recruited 404 IBD patients from Mexico D.F and Bogota City. The case-series in Mexico included a total of 200 patients with a diagnosis of IBD, 120 individuals had UC (60%) and 80 patients had CD (40%). The UC/CD ratio was 1.5: 1. The female-male ratio in UC was 1.5: 1 (60% vs 40%), and the CD ratio was 1.28: 1 (56.25% vs 47.75%). The Colombian case-series included a total of 204 patients with a diagnosis of IBD, 165 individuals had UC (80.88%), 36 patients had CD (17.65%) and 3 patients had an unclassifiable type of IBD (1.47%). The UC/CD ratio was 4.5:1. The female/male ratio in UC was 0.68:1 (40.61% vs 59.4%), and 0.8:1 (44.44% vs 55.56%) for CD. See Table 4.

Table 5 shows the most frequent clinical manifestations in IBD patients in both countries. The most frequent symptoms in both case-series were diarrhea, rectal bleeding and abdominal pain. Table 6 shows the prevalence ratio of the clinical manifestations in IBD patients of both cases-series. In Mexico, anorexia and weight loss were the clinical features most significantly related with UC, while abdominal pain was the symptom most frequently associated with CD. In relation with Colombian patients, bleeding was the clinical feature most significantly related with UC, while weight loss, abdominal pain, bowel obstruction and arthritis were the signs/symptoms most associated with CD. Diarrhea is equally prevalent in both pathologies.

Among Mexican patients, the most frequent anatomical involvement in CD patients were ileocolonic (37%) and colonic (30%) while the most frequent anatomical localization of UC patients was pancolitis with 55.83%, while left-sided colitis and proctitis were 34.17% and 10%, respectively. In Colombia, the most frequent anatomical involvement in CD patients were ileo-terminal (55%) and ileocolonic (39%), while the most frequent anatomical localization of UC patients was pancolitis with 39%, left-sided colitis 33.5% and proctitis 27.5%.

Table 3. Comparison of complete population prevalence and incidence rates of UC and CD as modelled by DisMod II and MIAMOD for Colombia in the years 2010 and 2015/6, and from SISPRO.

| Outcomes | Years | Ulcerative Colitis | | | | Crohn's Disease | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Male | Female | Male | Female | Male | Female | Male | Female |
|  | SISPRO | DisMod II† | MIAMOD | SISPRO | DisMod II† | MIAMOD | SISPRO | DisMod II† | MIAMOD | SISPRO | DisMod II† | MIAMOD |
| Prevalence | 2010 | 16.76 | 16.57 | 47.79 | 52.36 | 21.8 | 19.24 | 79.27 | 87.2 | 2.73 | 19.29 | 12.89 | 14.17 | 4.0 | 15.38 | 20.58 | 22.64 |
|  | 2015/6 | 20.25 | 26.6 | 47.85 | 54.3 | 26.72 | 28.2 | 79.39 | 87.33 | 2.56 | 20.2 | 12.9 | 14.19 | 3.1 | 16.6 | 20.61 | 22.68 |
| Incidence | 2010 | 13.7 | 0.81 | 1.69 | 1.86 | 18.4 | 0.48 | 2.52 | 2.81 | 2.6 | 0.31 | 0.44 | 0.48 | 3.9 | 0.29 | 0.61 | 0.7 |
|  | 2015/6 | 13.5 | 0.7 | 1.69 | 1.86 | 18.8 | 0.4 | 2.48 | 2.81 | 1.6 | 0.3 | 0.43 | 0.48 | 2.1 | 0.3 | 0.60 | 0.7 |

Prevalence inputs based on DISMOD-MR34,35
†19 (2010) and 19 (2016)
††15 (2010) and 14 (2016)
#12 (2010) and 12 (2016)
##9.7 (2010) and 8.7 (2016).

*Results from MIAMOD with an adjusted of 10% in the specific mortality data; NE: Not Estimated.

https://doi.org/10.1371/journal.pone.0228256.t003
At time of data collection, the most frequent clinical condition in Mexican UC patients was clinical remission (83%), followed by mild and moderate compromise (14% and 3% respectively). Out of 102 of patients in remission, 100 presented clinical remission, 68 biochemical remissions, 63 presented endoscopic remission and 28 patients presented histopathological remission. In Colombia, 58% of UC patients presented clinical remission, 26% being mild, and 16% moderate in the category of severity.

In the Mexican case-series, the relapse rate of the IBD patients was 67% (134/200). The UC relapse rate was 63.33% (n = 76), while the CD relapse rate was 72.5% (n = 58) without statistics difference (p = 0.15). In comparison, in the Colombian case-series the relapse rate for IBD was 57.4% (117/204); 58.2% in UC patients (96/165), and 58.3% in CD ones (21/36).

### Table 4. Clinical characteristics of UC and CD patients in the case-series of patients in Mexico City (n = 200) and Bogota (n = 204).

| Characteristics | Mexico | Colombia | p   |
|-----------------|--------|----------|-----|
| Ulcerative Colitis (n = 120) | Crohn’s Disease (n = 80) | Ulcerative Colitis (n = 165) | Crohn’s Disease (n = 36) | Non-specific (n = 3) | p   |
| Women n (%) | 72 (60) | 45 (56.25) | 0.59* | 67 (40.6) | 16 (44.4) | 2 (66.7) | 0.62* |
| Ever smoker (%) | 50 (41.6) | 42 (52.5) | 0.44† | 35 (21) | 8 (22) | - | 0.55* |
| Age at diagnosis—median (min-max) | 40 (28.5–49.5) | 49.5 (30.5–61.5) | 0.03³ | 38 (12–80) | 49 (12–85) | 51 (25–68) | 0.14⁹ |
| Symptoms starting age—median (min-max) | 38 (26.5–49) | 49 (29.5–60) | 0.01¹ | 37 (11–80) | 47 (11–84) | 51 (23–68) | 0.17⁹ |
| Time to diagnosis—median years (min-max) | 0 (0–1) | 0.5 (0–2) | 0.1⁴ | 0 (0–11) | 0.5 (0–2) | - | 0.39⁹ |

* X² tests
† Test U of Mann-Whitney.

https://doi.org/10.1371/journal.pone.0228256.t004

At time of data collection, the most frequent clinical condition in Mexican UC patients was clinical remission (83%), followed by mild and moderate compromise (14% and 3% respectively). Out of 102 of patients in remission, 100 presented clinical remission, 68 biochemical remissions, 63 presented endoscopic remission and 28 patients presented histopathological remission. In Colombia, 58% of UC patients presented clinical remission, 26% being mild, and 16% moderate in the category of severity.

In the Mexican case-series, the relapse rate of the IBD patients was 67% (134/200). The UC relapse rate was 63.33% (n = 76), while the CD relapse rate was 72.5% (n = 58) without statistics difference (p = 0.15). In comparison, in the Colombian case-series the relapse rate for IBD was 57.4% (117/204); 58.2% in UC patients (96/165), and 58.3% in CD ones (21/36).

### Table 5. Clinical signs and symptoms observed in IBD case-series of patients in both countries.

| Clinical signs and symptoms | Mexico (n = 200) | Colombia (n = 201) | p   |
|-----------------------------|-----------------|-------------------|-----|
| Ulcerative Colitis (n = 120) | Crohn’s Disease (n = 80) | p ¹ | Ulcerative Colitis (n = 165) | Crohn’s Disease (n = 35) | p   |
| Diarrhea n(%) | 118 (98.50) | 72 (90.00) | 0.01 | 151 (91.5) | 31 (86.1) | 0.85 |
| Rectal bleeding n(%) | 119 (99.20) | 72 (90.00) | 0.01 | 147 (89.1) | 24 (67.7) | 0.01 |
| Abdominal Pain n (%) | 92 (77.00) | 32 (40.00) | 0.06 | 127 (77) | 32 (88.9) | 0.1 |
| Weight Loss n(%) | 43 (35.83) | 52 (65.00) | < 0.01 | 79 (47.9) | 23 (63.9) | 0.08 |
| Bowel obstruction n (%) | 17 (14.16) | 19 (23.75) | 0.07 | 11 (6.7) | 5 (13.9) | 0.05 |
| Anorexia n(%) | 24 (20.00) | 39 (48.75) | < 0.01 | 42 (25.4) | 13 (36.1) | 0.04 |
| Fatigue n(%) | 37 (30.83) | 45 (56.25) | < 0.01 | 8 (4.8) | 4 (11.1) | 0.23 |
| Others symptoms n (%) | 2 (1.74) | 11 (13.75) | 0.01 | 6 (3.6) | 0 | 0.5 |
| Arthritis/arthritisias n(%) | 66 (55.00) | 45 (56.25) | 0.76 | 9 (5.4) | 5 (13.9) | 0.05 |

* X² tests

https://doi.org/10.1371/journal.pone.0228256.t005
In the UC group, 27.63% (21/76) of the Mexican patients presented the relapse between the first five years after diagnosis and the same number of patients relapsed after five years (21/76). Regarding the CD patients who presented relapses, 31.03% (18/58) and 22.41% (13/58) relapsed during the first five years and after the fifth year from diagnosis, respectively.

In Colombia, for those 96 UC patients who relapsed, 23% did so during the first 12 months after diagnosis, 53% between one year and five years after diagnosis, and 22% after five years, with 2% of patients with missing information. For those 21 CD patients who relapsed, 24% did in the first 12 months after diagnosis, 62% within the first to fifth year and the remaining 14%, after 5 years to diagnosis.

In Mexican case-series, 38% of UC cases (n = 46) and 72.5% of CD ones (n = 59) required hospitalization. The median number of hospitalizations in patients with UC was 1 (min-max: 1–4) and 2 (min-max: 1–15) in CD patients. The percentage of UC patients who required surgery during the follow-up was 10% (n = 12), contrasting with CD patients, who needed a surgery in 58.75% (n = 47) of cases.

In Colombian case series, 27% of UC cases (n = 45) and 36% of CD ones (n = 13) required hospitalization. The median number of hospitalizations in patients with ulcerative colitis was 1 (min-max: 1–8) while the median number of hospitalizations in patients with CD was 2 (min-max: 1–11). The percentage of UC patients who required surgery during the follow-up was 2% (n = 3), contrasting with CD patients, who needed surgery in 28% (n = 10) of cases.

Regarding the treatment pattern distribution, in Mexican UC case-series, 5-aminosalicylic acid (5-ASA) was the most frequent choice (98%), followed by steroids (48%), azathioprine (47%) and biologicals (22%); and among the CD patients, the most frequent were 5-ASA (98%), azathioprine (76%), biologicals (76%) and steroids (64%). In Colombia, 97% of UC patients received 5-ASA, and 56%, 51% and 20% used steroids, azathioprine and biological drugs, at any time during follow-up, respectively. For CD patients, the most frequent were steroids (86%), followed by azathioprine (84%), biologicals (64%) and finally 5-ASA (39%).

### Table 6. Prevalence ratio of selected clinical manifestations in UC versus CD patients, by country (2018).

| Variable            | Mexico | Colombia |
|---------------------|--------|----------|
|                     | Prevalence ratio UC vs CD | IC 95% | p     | Prevalence ratio UC vs CD | IC 95% | p     |
| Diarrhea            | 0.97   | 0.82–1.13 | 0.67  | 1.07 | 0.75–1.52 | 0.67  |
| Bleeding            | 1.04   | 0.89–1.22 | 0.58  | 2.07 | 1.05–4.05 | <0.01 |
| Abdominal Pain      | 0.81   | 0.69–0.94 | <0.01 | 0.79 | 0.73–0.86 | 0.04  |
| Weight Loss         | 1.32   | 1.03–1.69 | 0.02  | 0.81 | 0.72–0.92 | <0.01 |
| Bowel obstruction   | 1.27   | 0.88–1.82 | 0.15  | 0.79 | 0.56–1.11 | 0.06  |
| Anorexia            | 1.57   | 1.12–2.20 | <0.01 | 0.85 | 0.75–1.03 | 0.06  |
| Arthritis           | 1.01   | 0.83–1.22 | 0.92  | 0.77 | 0.52–1.14 | 0.07  |

*Ulcerative Colitis
§Crohn’s disease

https://doi.org/10.1371/journal.pone.0228256.t006
Discussion

This work presented novel estimates of IBD disease burden and clinical features of affected patients in two Latin American countries, Mexico and Colombia. Given the lack of information on nationwide prevalence and incidence of IBD, we estimated them through different mathematical models and provided supplementary information coming from large official health system databases. To our knowledge, this is the first study doing so in both countries. In the case of Mexico, the official health system databases do not report persons with hospitalizations related to IBD. In Colombia, on the other hand, the cumulative proportion of IBD patients registered in SISPRO represents a good approximation of the country prevalence considering that most cases require the health system intervention and that the database is updated annually.

When we first analyzed the SISPRO incidence, we expected the biggest incidence rate to be for 2010, but we obtained similar values for incidence over the years that we included in the analysis. We consider two situations that may impact on the number of cases that have been registered in SISPRO: 1) the uploading of the cases depends on whether the administrative employees and physicians do that; and 2) the coverage of SISPRO has been growing in the last years and it is possible that each year different health centers are incorporated to the registry.

For Mexico, our study estimated a UC prevalence of 71 per 100,000 inhabitants (44 for males and up to 98 for females) in 2015/16; and of 18 for CD, (20 for males and up to 16 for females). The UC incidence per 100,000 inhabitants was 2.30 (1.55 for males and up to 3.05 for females), and for CD, it was 0.66 (0.75 and up to 0.57 for males and females respectively).

For Colombia, the UC prevalence was 70.5 per 100,000 inhabitants (54 for males and up to 87 for females in 2015/6); and for CD it was 21.5 per 100,000 inhabitants (20 for males and up to 23 for females). The UC incidence per 100,000 inhabitants was 2.3 per 100,000 inhabitants (1.86 for males and up to 2.81 for females), and for CD it was 0.59 per 100,000 inhabitants (0.48 for males and up to 0.7 for females).

The IBD prevalence figures obtained with MIAMOD for Mexico and Colombia were higher than those reported in a previous systematic review carried out by our research team in Latin American countries, in which the prevalence for UC ranged from 0.99 to 44.3 per 100,000 inhabitants, and from 0.24 to 14.90 for CD.[18]

IBD epidemiology has been studied in developed countries in a more comprehensive way, as noted by Ng et al in a study showing a rising incidence in industrialized countries in Africa, Asia, and South America since 1990.[8] The highest reported prevalence rates for IBD were in Europe (UC, 505 per 100,000 persons; CD, 322 per 100,000 persons) and in North America (UC, 286 per 100,000 persons in USA; CD, 319 per 100,000 persons in Canada).[9,10] Differences between countries could be explained by several factors, including migration rates, genetic profiles, environment or socioeconomic factors, and also by methodological limitations of epidemiologic studies, including design or diagnostic approach, differences in population characteristics, and access to health care.[39][40] Of note, all of those prevalence and incidence rates are much higher than those coming from a few well-conducted Latin American population-based studies.[18]

A study has revealed a decreasing geographical North-South gradient for IBD incidence. One possible explanation would be that in northern regions, there is low exposure to sunlight, as well as vitamin D plasma levels.[41] However, its causal relationship with IBD is still uncertain. The lower IBD prevalence in Mexico and Colombia compared to other countries in North America could also be due to their latitude, but considering the absence of population-based prevalence studies this theory deserves further research.
The varying range of our estimations can be partly explained by structural differences between models. DisMod II is a state-transition model which requires the population structure, general and specific mortality, remission and prevalence as input. On the other hand, MIAMOD is a model of multiple and polynomial regressions that uses all-cause mortality, specific mortality, relative survival and population structure as input. As stated, MIAMOD model is a method primarily developed for cancers with long survival, to be used in countries with a sound surveillance system capable of adequately capturing survival rates. It has been used for colon and breast cancer and could potentially be applied to other chronic conditions like IBD. Also as there might be some concerns regarding the quality of the survival data used for feeding MIAMOD, we decided to use the 14-year Denmark’s nationwide cohort, as the best available surrogate input of the age-adjusted survival. Although it can be argued that IBD patients survival in a low- and middle-income country could be lower than in a high-income country, the magnitude of the difference would be minor since IBD mortality is low. In general, MIAMOD prevalence and incidence estimates were higher than DisMod II model estimations.

The DisMod II model estimations and SISPRO information were quite similar regarding prevalence. Yepes Barreto et al in 2010 published a small case-series of adult population from a social security institution in Cartagena, and estimated an overall IBD prevalence in their population of 29 per 100,000 (95%CI 17–40), which is in the range of our estimations. Additionally, another source reinforced our estimations for prevalence. In 2016, the Health Metrics and Evaluation (IHME) published the updated Global Burden of Disease (GBD) for prevalence and incidence in Mexico and Colombia, in which they used the DisMod-MR model. This model is based on Bayesian meta-regression and uses an extensive temporal series of population surveys as input. For Mexico, the GBD study estimated a 2016 UC prevalence per 100,000 inhabitants of 22 for males and 16 for females. For CD, it estimated a prevalence per 100,000 inhabitants of 12 and 9 for males and females, respectively. For Colombia, the GBD study estimated a 2016 UC prevalence per 100,000 inhabitants of 22 for males and 17 for females. For CD, it estimated a prevalence per 100,000 inhabitants of 12 and 9.4 for males and females, respectively. However, we identified some inconsistencies in the GBD reported incidence data for both countries, like the finding of higher incidence than prevalence rates.

We also analyzed the UC and CD GBD prevalence compared with the best quality population-based nationwide studies. With the exception of two cases with just a one-digit prevalence (Romania and Taiwan), in all cases (Hungary, Japan, Barbados, Sweden, Germany, Denmark, Canada, Norway and Finland) GBD largely under-estimated the real prevalence. For this reason, we consider that our DisMod II estimations are conservative and the real prevalence could probably be higher and closer to our MIAMOD-derived estimations.

Our study had several limitations related mainly to the quality of available data and many assumptions required modelling the IBD incidence and prevalence by these novel methods. For example, the exercise of MIAMOD outside the field of oncology, with information only for a relatively small number of years and using foreign survival data, may threaten the validity of its estimates. Additionally, since the relative survival rates were not available, we used the observed absolute survival rates that could result in underestimation of the real prevalence rates.

On the other hand, the multiple methodological and epidemiological verification sources used to increase the confidence in our estimations represent a clear strength of our study. In Colombia, SISPRO databases also provided further valuable information like the number of hospital discharges, emergency and outpatient visits and treatment pattern by IBD type and by sex for all ages. A limitation of this database is that if a patient does not contact the health system, then that IBD case is ignored.
We found similar results in other case-series in Mexico and Colombia but with some differences. [44–47]

A recent multicentric nationwide study evaluated the clinical and socio-demographical characteristics of 2645 Mexican IBD patients from February to October 2017, with results that are consistent with our case-series.

Regarding the description of clinical phenotypes of Colombian IBD cases, Baños et al also reported a case-series of 202 patients drawn from a convenience sample in Medellín, Colombia. IBD patients (CD 15.8%, UC 80.7%) who consulted the reference center Hospital Pablo Tobon Uribe between August 2001 and July 2009 were systematically evaluated.[46] A slight predominance in the female group (56.4%) and an average age of onset of 37 years of age was found. The percentage of patients with extra-intestinal involvement was 27.7% and the time of diagnosis from the onset of symptoms was 9.2 months for UC and 13.2 for CD. The 35% of patients affected with UC presented extensive colitis and only 23.1% of them showed severe symptoms. The anatomical compromise of the patients with CD was predominantly ileocolonic (50%) and the inflammatory, stenotic and perianal behavior was of similar proportions in this group. The proportion of patients with UC who were in clinical remission was higher than that published by Baños (58.7% vs 17.2%) while the proportion of patients with mild UC was similar for both series of cases, probably due to newer available treatments.[46] Consistently, the proportion of patients with UC who had been hospitalized was 30.4% and 58.1% for CD while the value for the other case-series was 42.9% and 75% respectively.[46] Biological therapy was used in 7.4% of patients with UC and in 47% of patients with CD and its use was related to the risk of requiring surgical treatment in the two diseases.[48]

A previous large case-series of 848 patients with UC in Mexico reported by Yamamoto-Furusho in 2009[20] showed that the largest proportion of patients diagnosed with this pathology is between 21 and 30 years of age. The mean age at diagnosis was 31.3 years, while the median age was 38 years for patients with UC, lower than the ones in our study. The main clinical manifestations such as diarrhea, bleeding and abdominal pain were consistent with our case-series, as was the percentage of patients who required surgery (10%).[20] In relation with the distribution of the extent of the UC, it was consistent with our study. The comparative treatment pattern varied between our more recent series and the Yamamoto series: 5 ASA (98 vs. 64%), steroids (48 vs. 33%), azathioprine (47 vs 28%) and biologicals (22 vs 1%), respectively.[20] Another small case-series presented similar clinical manifestations and surgery requirements but different treatment patterns: 5 ASA (100%), steroids (7%), and biologicals (7%).[24] Other case-series of 104 patients with IBD showed that out of the 75 patients with UC, 55% had mild disease, 30% moderate disease and 15% severe disease.[23] Another study by Yamamoto-Furusho et al found that elderly patients with CD had a mild clinical course characterized by long-term remission and no escalation to immunosuppressive and anti-tumor necrosis factor therapy.[49]

Of interest, a cohort analysis of 184 cases in Mexico found that pancolitis, hypoalbuminemia and previous hospitalizations were the strongest predictors of procto-colectomy.[50] One study found a higher prevalence of left-sided colitis, higher mortality, and higher usage of biological agents in Mexican population than in Mexican-American population, supporting the role of environmental factors on clinical characteristics of IBD.[24]

The larger case-series in LAC Countries are from 1946 to date are from Argentina [14,51,52], Barbados[13], Brazil[14,53–65], Chile[66–68], Cuba[69], Peru[70,71], Puerto Rico [72–75] and Uruguay.[76–78] Most CD localizations were ileal-colonic and CD behavior was mostly inflammatory, followed by penetrant or stenotic. Perianal disease was identified roughly in one out of four cases. Regarding UC extension, it varied a lot, but extensive colitis was the most prevalent in these cases series, followed by left-sided and proctitis.
Conclusion

Despite the aforementioned difficulties in approaching real IBD estimations in a scenario of paucity of representative data, we showed that the burden of IBD in Mexico and Colombia should not be considered negligible. Moreover, given the high variability observed in the reporting of IBD epidemiology worldwide, depicting real-world burden of these conditions remains to be a global challenge.

Supporting information

S1 File. Figures 1 to 4.
(DOCX)

S2 File. Tables 1 to 6.
(DOCX)

Acknowledgments

We appreciate the valuable contribution of Aline Medeiros Samora and Yiting Wang in the preparation of the manuscript.

Author Contributions

Conceptualization: Agustín Ciapponi, Juan De Paula, Ariel Bardach.

Data curation: Natalie Claire Soto, Álvaro Ciganda.

Formal analysis: Agustín Ciapponi, Sacha Alexis Virgilio, Mabel Berrueta, Natalie Claire Soto, Álvaro Ciganda, Ariel Bardach.

Funding acquisition: Agustín Ciapponi.

Investigation: Agustín Ciapponi, Sacha Alexis Virgilio, Mabel Berrueta, Natalie Claire Soto, Moisés Freddy Rojas Illanes, Briseida Rubio Martinez, Johana Gamba, Carlos Arturo González Salazar, José Nicolás Rocha Rodriguez, Ariel Bardach.

Methodology: Agustín Ciapponi, Sacha Alexis Virgilio, Mabel Berrueta, Natalie Claire Soto, Ariel Bardach.

Project administration: Agustín Ciapponi.

Resources: Agustín Ciapponi, Sacha Alexis Virgilio, Natalie Claire Soto.

Software: Natalie Claire Soto.

Supervision: Agustín Ciapponi.

Validation: Agustín Ciapponi, Natalie Claire Soto, Ariel Bardach.

Writing – original draft: Agustín Ciapponi, Sacha Alexis Virgilio, Ariel Bardach.

Writing – review & editing: Agustín Ciapponi, Sacha Alexis Virgilio, Johana Gamba, Carlos Arturo González Salazar, José Nicolás Rocha Rodriguez, Bruno Scarpellini, Ana Maria Bravo Perdomo, Gerardo Machnicki, Leandro Aldunate, Juan De Paula, Ariel Bardach.

References

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066–2078. https://doi.org/10.1056/NEJMoa0804647 PMID: 19923578
2. Hendrickson BA, Gokhale R, Cho JH. Valquiria da Costa da Silva J. Value in Biomarkers for IBD. 2002; 15: 79–94. https://doi.org/10.1111/1439-0525.01203

3. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: The declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014; 39: 645–659. https://doi.org/10.1111/1472-0243.12650

4. Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical cost of managing IBD patients: A Canadian population-based study. Inflamm Bowel Dis. 2012; 18: 1498–1508. https://doi.org/10.1002/ibd.21878

5. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 577–585. https://doi.org/10.1111/j.1365-2036.2006.02809.x

6. Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al. Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006; 55: 510–518. https://doi.org/10.1136/gut.2005.072793

7. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013; 11: 43–48. https://doi.org/10.1016/j.cgh.2012.09.026

8. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017; 390: 2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0

9. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142: 46–54.e42. https://doi.org/10.1053/j.gastro.2011.10.001

10. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504–1517. https://doi.org/10.1053/j.gastro.2004.01.063

11. Appleyard CB, Hernandez G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm Bowel Dis. 2004; 10: 106–111. https://doi.org/10.1097/01.MIB.0000091113.74998.53

12. Buenavida G, Casanias A, Vasquez C, De Souza M, Martinez L, Gardi I, et al. Incidence of inflammatory bowel disease in five geographical areas of Uruguay in the biennial 2007–2008. Acta Gastroenterol Latinoam. 2011; 41: 281–287. PMID: 22292223

13. Edwards CN, Griffith SG, Hennis AJ, Hambleton IR. Inflammatory bowel disease: incidence, prevalence, and disease characteristics in Barbados, West Indies. Inflamm Bowel Dis. 2008; 14: 1419–1424. https://doi.org/10.1002/ibd.20495

14. Parente JML, Coy CSR, Campelo V, Parente MPPD, Costa LA, da Silva RM, et al. Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil. World J Gastroenterol. 2015; 21: 1197–1206. https://doi.org/10.3748/wjg.v21.i4.1197

15. Souza MH, Troncon LE, Rodrigues CM, Viana CF, Onofre PH, Monteiro RA et al. Trends in the occurrence (1980–1999) and clinical features of Crohn’s disease and ulcerative colitis in a university hospital in southeastern Brazil. Arq Gastroenterol. 2002; 39: 98–105. https://doi.org/10.1590/s0004-2803200200020012

16. Victoria CR, Sassak LY NH. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of Sao Paulo State, Brazil. Arq Gastroenterol. 2009; 20. https://doi.org/10.1590/s0004-28032009000100009

17. Vendrell R, Venegas HL, Perez CM, Morell C, Roman RV TE. Differences in prevalence of inflammatory bowel disease in Puerto Rico between commercial and government-sponsored managed health care insured individuals. Bol Asoc Med P R. 2013; 105: 15–19. PMID: 23882984

18. Calderon M, Minckas N, Nunez S, Ciapponi A. Epidemiology of Ulcerative Colitis in Latin America: A Systematic Review. Value Heal Reg issues. 2018; 17: 126–134. https://doi.org/10.1016/j.vhri.2018.03.010

19. Yamamoto-Furusuho JK, Rodriguez-Borres L, Gonzalez-Contreras OH, Martinez-Benitez B. Prevalence and clinical features of indeterminate colitis in Mexico: a 17-year study. Rev Gastroenterol Mex. 2010; 75: 30–35. Available: internal-pdf://190.67.140.1/Yamamoto-Furusuho2010.pdf

20. Yamamoto-Furusuho JK. Clinical epidemiology of ulcerative colitis in Mexico: A single hospital-based study in a 20-year period (1987–2006). J Clin Gastroenterol. 2009; 221–224. Available: internal-pdf://0330088355/Yamamoto-Furusuho2009.pdf

21. Yamamoto Furusho JK. Tratamiento de la enfermedad inflamatoria intestinal. Rev Gastroenterol Mex. 73: 47–49. Available: internal-pdf://68.3.123.161/Yamamoto2016.pdf
22. Sandoval ER, Bosques Padilla FJ. Enfermedad inflamatoria intestinal: realidad en México. Rev Gastroenterol Mex. 73: 38–42. Available: internal-pdf://0525892513/Sandoval2008.pdf
23. Bosques-Padilla FJ, Sandoval GER, Martínez-Vazquez MA, Garza E. G, Maldonado-Garza HJ. Epidemiology and clinical characteristics of ulcerative colitis in north-eastern Mexico. Rev Gastroenterol Mex. 2011; 34–38. Available: internal-pdf://232.138.161.93/BosquesPadilla2011.pdf PMID: 21592901
24. De la Cruz-Guillén AA, Cortés-Espinosa T, Sánchez-Chávez X, López Gómez JG, Quintero Aguilar G, Reyes Zermeño MG, et al. Clinical behavior of chronic nonspecific ulcerative colitis in patients of CMN 20 de Noviembre, ISSSTE, and comparison with American bibliography. Med Interna Mex. 2011; 224–230. Available: internal-pdf://120.193.119.251/DeLaCruz2011.pdf
25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke J. Annals of Internal Medicine Academia and Clinic The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting. Ann Intern Med. 2007; 147: 573–578. https://doi.org/10.7326/0003-4819-147-8-200710160-00010 PMID: 17938396
26. SSA IMSS-Opportunities, ISSSTE, PEMEX, SEDENA, SEMAR, Otros I, editor. Dirección General de Información en Salud (DGIS). Bases de datos sobre Egresos Hospitalarios. Sector Salud 2004–2015. 2012. Available: http://www.dgis.salud.gob.mx/contenidos/basesdedatos/std_egresoshospitalarios_gobmx.html
27. International Classification of Diseases (ICD). Geneva, Switzerland.: World Health Organization; 1992.
28. Salud S de, editor. Norma Oficial Mexicana NOM-035-SSA3-2012, en materia de información en salud. México: Diario Oficial de la Federación.; 2012. Available: http://www.cnndh.org.mx/DocTR/2016/JUR/A70/01/JUR-20170331-NOR18.pdf
29. Proyecciones del Consejo Nacional de Población México. 2017. Available: http://www.conapo.gob.mx/ES/CONAPO/Proyecciones_Datos
30. Dirección General de Información en Salud (DGIS) Defunciones: cifras oficiales de- finitivas y egresos hospitalarios Sector Salud. 2017. Available: http://dgis.salud.gob.mx/
31. Sistema Integral de Información de la Protección Social (SISPRO).
32. Departamento Administrativo Nacional de Estadística (DANE).
33. Barendregt JJ, van Oortmarssen GJ, Vos T, Murray CJL. A generic model for the assessment of disease epidemiology: The computational basis of DisMod II. Popul Health Metr. 2003; 1: 1–8. https://doi.org/10.1186/1478-7954-1-1
34. Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. Seattle, WA: IHME, University of Washington; 2017. Available: http://vizhub.healthdata.org/gbd-compare.
35. GBD. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2017. Available from http://ghdx.healthdata.org/gbd-results-tool. 2016.
36. De Angelis G, De Angelis R, Frova L, Verdecchia A. MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data. Comput Methods Programs Biomed. 1994; 44: 99–107. https://doi.org/10.1016/0169-2607(94)90091-4 PMID: 7988122
37. Coverage of civil registration system (UNSD).
38. Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology. 2017; 152: 313–321.e2. https://doi.org/10.1053/j.gastro.2016.10.020 PMID: 27793607
39. Molodecky NA, Panacchione R, Ghosh S, Barkema HW, Kaplan GG. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17: 1792–1799. https://doi.org/10.1002/ibd.21511 PMID: 21744435
40. Mudambi K, Bass D. Vitamin D: a brief overview of its importance and role in inflammatory bowel disease. Trans Gastroenterol Hepatol. 2018; 3: 31. https://doi.org/10.21037/tgh.2018.05.03 PMID: 29971262
41. Vad ND, Green A, Rubin KH. Inflammatory Bowel Disease in Denmark: Changes in Epidemiological Characteristics and Colorectal Cancer Incidence from 2000–2013. Dan Med J.
42. Yepes Barreto I, Carmona R, Díaz F, Marín-Jiménez I. Prevalencia y caracteristicas demográficas de la enfermedad inflamatoria intestinal en Cartagena, Colombia. Rev Colom Gastroenterol. 2010; 25: 107–111.
43. Sarmiento A, Toledo J, Bozada K, Valenzuela J, Jaramillo C, Angulo F, Casanova A, Bermúdez E, et al. Clinical and sociodemographical characteristics of inflammatory bowel disease in Mexico: Multicentric
Enfermedad inflamatoria intestinal en Colombia: ¿Está cambiando nuestro perfil epidemiológico?

Pineda Ovalle L. Enfermedad inflamatoria intestinal en Colombia: ¿Está cambiando nuestro perfil epidemiológico? Rev Colomb Gastroenterol. 2010; 25: 235–238.

Choquet A, Yamamoto-Furusho JK, Reyes E, Takahashi-Monroy T, Vargas-Vorackova F, Uscanga L. [Predictors of colectomy in patients with ulcerative colitis. A cohort analysis of 184 cases]. Rev Invest Clin. 2004; 56: 11–15. PMID: 1514036

Dolcini H, Arabehety JT, Stapler NM. Ulcerative colitis. Follow-up of 100 patients, with some comments on the general features of this disease in Argentina. Am J Proctol. 1967; 18: 132–135. PMID: 6041799

Ruiz JA, Orsi M, Aliboni V, Kakisu H, Busoni V, Contreras MB, et al. M1131 Pediatric Inflammatory Bowel Disease in a Latin-American Population from Buenos Aires. Multicenter Study. Gastroenterology. 2009; 136: A-356. https://doi.org/10.1016/s0016-5085(09)61634-6

de Barros PAC, da Silva AMR, Neto MA dos, Carvalho ATP, Silva K dos S, SA Santana GO, Lyra LG, Santana TC, Dos Reis LB, Guedes JC, Toralles MB, et al. Bone mineral density and epidemiologic profile and clinical characteristics of patients with intestinal inflammatory disease. J Coloproctology. 2017; 37: 273–278. https://doi.org/10.1016/j.jcol.2017.06.004

Campos FG, Teixeira MG, Scavanini A, Almeida MG, Nahas SC, Cecconello I. Intestinal and extraintestinal neoplasia in patients with inflammatory bowel disease in a tertiary care hospital. Arq Gastroenterol. 2013; 123–129. https://doi.org/10.1590/s0004-28032013000200021 PMID: 23903622

da Silva BC, Lyra AC, Mendes CMC, Ribeiro CPO, Lisboa SRO, de Souza MTL, et al. The Demographic and Clinical Characteristics of Ulcerative Colitis in a Northeast Brazilian Population. Biomed Res Int. 2015; 2015: 1–8. https://doi.org/10.1155/2015/359130 PMID: 26509150

Delmondes LM, Nunes MO, Azevedo AR, Oliveira MM de S, Coelho LER, Torres-Neto J da R. Clinical and Sociodemographic Aspects of Inflammatory Bowel Disease Patients. Gastroenterol Res. 2015; 8: 207–215. https://doi.org/10.14740/gr649w PMID: 27785298
64. Hardt MR, Kotze PG, Teixeira FV, Ludvig JC, Malluta EF, Kleinubing Junior H, et al. Epidemiological profile of 175 patients with Crohn’s disease submitted to biological therapy. J Coloproctol (Rio Janeiro). 2012; 32: 395–401. https://doi.org/10.1590/s2237-93632012000400006

65. Kleinubing-Junior H, Pinho M de SL, Ferreira LC, Bachhold GA, Merki A. Perfil dos pacientes ambulatoriais com doenças inflamatórias intestinais. ABCD Arq Bras Cir Dig (São Paulo). 2011; 24: 200–203. https://doi.org/10.1590/s0102-67202011000300004

66. Simian D. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol. 2016; 22: 5267. https://doi.org/10.3748/wjg.v22.i22.5267 PMID: 27298570

67. Figueroa C C, Quera P R, Valenzuela E J, Jensen B C. [Inflammatory bowel disease: experience of two Chilean centers]. Rev Med Chil. 2005; 133: 1295–1304. https://doi.org/S0034-98872005001100004 PMID: 16446852

68. Quintana C, Galleguillos L, Benavides E, Quintana JC, Zúñiga A, Duarte I, et al. Clinical Diagnostic Clues in Crohn’s Disease: A 41-Year Experience. ISRN Gastroenterol. 2012; 2012: 1–6. https://doi.org/10.5402/2012/285475 PMID: 23213555

69. Fragoso Arbelo T, García Bacallao E, García Pérez W, Trujillo Toledo. María Elena, Rodríguez Ramírez E, García Soto E, et al. Revista cubana de pediatría. Revista Cubana de Pediatría. Centro Nacional de Informacion de Ciencias Medicas; 1946. Available: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312002000300002&lng=es&nrm=iso&tlng=es

70. Paredes-Méndez J, Moreno GO, Rivas-Plata ALM, et al. [Epidemiological and clinical characteristics of inflammatory bowel disease in a tertiary referral hospital in Lima-Peru]. Rev Gastroenterol Peru. 2016; 36(3):209–218. PMID: 27716757

71. Bendano T, Frisancho O. [Clinical and evolutive profile of Crohn’s disease in Hospital Rebagliati (Lima-Peru)]. Rev Gastroenterol Peru. 2010; 30(1):17–24. PMID: 20457220

72. Torres EA, Cruz A, Monagas M, Bernal M, Correa Y, Cordero R, et al. Inflammatory Bowel Disease in Hispanics: The University of Puerto Rico IBD Registry. Int J Inflamm. 2012; 2012: 1–5. https://doi.org/10.1155/2012/574079 PMID: 22195289

73. Moreno JM, Rubio CE, Torres EA. [Inflammatory disease of the gastrointestinal tract at the University Hospital, Medical Center, Puerto Rico. 1980–87]. Bol Asoc Med P R. 1989; 81: 214–218. PMID: 2765040

74. Micames C, Zaiter J, Nigaglioni A. Clínico-epidemiological features of 102 consecutive cases of ulcerative colitis in Puerto Rico. Bol Asoc Med P R. 1983; 75: 106–109. PMID: 6577863

75. Melendez JD, Larregui Y, Vazquez JM, Carlo VL, Torres EA. Medication profiles of patients in the university of puerto rico inflammatory bowel disease registry. P R Health Sci J. 2011; 30(1):3–8. PMID: 21449490

76. Luciano MJ, Noria A, Iade B. P688 Demographic, clinical, and therapeutic characteristics of a cohort of 238 patients with ulcerative colitis from two medical centres from Uruguay. J Crohn’s Colitis. 2018; 12: S458–S459. https://doi.org/10.1093/ecco-jcc/jjx180.815

77. Iade B, Bianchi C, Espindola F. Características clínicas de presentación y seguimiento de una cohorte de 121 pacientes con colitis ulcerosa crónica en Uruguay. Rev Médica del Uruguay. 2005; 298–302. Available: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-03902005000400006&lang=pt

78. Iade B, Bianchi C, Espindola F. Características clínicas de presentación y evolutivas de una cohorte de 48 pacientes con enfermedad de Crohn en Uruguay. Rev Médica del Uruguay. 2005; 21: 303–307. Available: http://www.scielo.edu.uy/scielo.php?script=sci%7B_%7Darttext%7B%7Dpid=S1688-03902005000400007%7B%7Dlang=pt%0Ahttp://www.scielo.edu.uy/pdf/rmu/v21n4/v21n4a07.pdf